SAB Total Assets from 2010 to 2025
| SABS Stock | USD 1.62 0.07 4.52% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 96.5 M | Current Value 63.5 M | Quarterly Volatility 28.8 M |
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 4.5 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 18.54, Dividend Yield of 0.0 or PTB Ratio of 0.63. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
SAB | Total Assets |
Latest SAB Biotherapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of SAB Biotherapeutics over the last few years. Total assets refers to the total amount of SAB Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in SAB Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. SAB Biotherapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 83.94 M | 10 Years Trend |
|
Total Assets |
| Timeline |
SAB Total Assets Regression Statistics
| Arithmetic Mean | 38,177,990 | |
| Geometric Mean | 29,956,850 | |
| Coefficient Of Variation | 75.33 | |
| Mean Deviation | 25,218,044 | |
| Median | 18,003,555 | |
| Standard Deviation | 28,760,997 | |
| Sample Variance | 827.2T | |
| Range | 78.5M | |
| R-Value | 0.81 | |
| Mean Square Error | 297.8T | |
| R-Squared | 0.66 | |
| Significance | 0.0001 | |
| Slope | 4,922,615 | |
| Total Sum of Squares | 12407.9T |
SAB Total Assets History
Other Fundumenentals of SAB Biotherapeutics
SAB Biotherapeutics Total Assets component correlations
Click cells to compare fundamentals
About SAB Biotherapeutics Financial Statements
SAB Biotherapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although SAB Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in SAB Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on SAB Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 96.5 M | 63.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.